DeepSight Technology

Executive Summary

DeepSight Technology is a privately held medical device company based in Menlo Park, California, focused on revolutionizing interventional imaging through its proprietary NeedleVue™ platform. Founded in 2017, the company aims to provide real-time, high-resolution visualization within the body during minimally invasive procedures such as biopsies, ablations, and cardiac interventions. By simultaneously showing target anatomy and instrument position, DeepSight's technology seeks to enhance precision, efficiency, and control for physicians. The company operates in the ophthalmology and medical devices sectors, leveraging advanced imaging to improve patient outcomes. While specific financial details, funding history, and development stage are not publicly disclosed, DeepSight's innovative approach positions it as a potential disruptor in the interventional imaging market. Given its early-stage nature and limited public information, the company's progress remains largely under the radar, but its technology could address significant unmet needs in procedural guidance.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for NeedleVue™ System60% success
• Q4 2026Completion of Pivotal Clinical Trial for NeedleVue™50% success
• TBDStrategic Partnership or Licensing Agreement with Major Medical Device Company40% success